FRANKFURT, July 21 (Reuters) - Germany's Bayer said on Friday a cancer treatment for patients with a type of tumour often caused by asbestos had failed to meet its main goal in a clinical trial. The compound, known as read the article the mesothelioma center anetumab ravtansine, "did not meet its primary endpoint of progression-free survival" for patients with mesothelioma, Bayer said, adding it was disappointed by the results. "Malignant pleural mesothelioma is a very difficult-to-treat tumour, and we had hoped for a better outcome for patients," said Robert LaCaze, executive vice president and head of the oncology strategic business unit at Bayer.
He said Bayer would continue to study the usefulness and safety of the compound for other tumour types. (Reporting by Tom Sims; Editing by Mark Potter) mesothelioma of lung
If you adored this information and you would like to obtain even more information pertaining to he said asbestos in the home kindly see our site.